Nankivell Brian J, Viswanathan Seethalakshmi
Department of Renal Medicine, Westmead Hospital, Westmead, NSW, Australia.
Department of Tissue Pathology and Diagnostic Oncology, ICPMR, Westmead Hospital, Westmead, NSW, Australia.
Transplantation. 2025 Feb 1;109(2):376-385. doi: 10.1097/TP.0000000000005224. Epub 2024 Sep 30.
Microvascular inflammation (MVI) is an important pathological feature of antibody-mediated rejection (AMR). How posttransplant time affects its clinicopathological expression is little understood.
This retrospective, single-center study screened 3398 kidney transplant biopsies and dichotomized 202 MVI ≥ 2 (Banff glomerulitis + peritubular capillaritis ≥ 2) samples by 9-mo median incidence time for comparison.
The prevalence of MVI ≥ 2 was 12.4% in transplant kidneys, which failed more frequently than propensity-matched normal controls (n = 202; P < 0.001). Epidemiological risk factors for early MVI ≥ 2 were delayed graft function, prior AMR, and circulating donor-specific antibodies (DSAs+). Prior recipient sensitization occurred in 72.3%. Early MVI ≥ 2 was classified AMR in 65.3% and cellular rejection in 34.7%, and demonstrated excellent functional recovery and graft survival comparable to normal control kidneys. Late MVI ≥ 2 was predicted by younger (18 = 29 y) age, female recipient, living-donation, prior methylprednisolone, cyclosporine (versus tacrolimus, levels <5 ng/mL), absent antiproliferative therapy, and DSA+ using multivariable epidemiological modeling. Nonadherence caused 49.5%, with iatrogenic minimization responsible for 47.5%, usually for recipient infection. Late MVI ≥ 2 was because of AMR in 93.1%, and characterized by greater interstitial fibrosis, tubular atrophy, complement degradation split-product 4d (C4d) staining of peritubular capillaries+, endothelial C4d staining of glomerular capillaries+, transplant glomerulopathy and vasculopathy scores, DSA strength, and graft failure than early MVI ≥ 2 or normal transplant kidneys. Death-censored graft survival in 149 unique MVI ≥ 2 kidneys was independently determined by nonadherence, serum creatinine, proteinuria, DSA+, Banff C4d staining of peritubular capillaries+, and chronic interstitial fibrosis scores. MVI score and time lost significance using multivariable Cox regression.
The changing expression of MVI ≥ 2 over time is best explained by differences in underimmunosuppression and microvascular injury from AMR impacting allograft function and survival.
微血管炎症(MVI)是抗体介导的排斥反应(AMR)的重要病理特征。移植后时间如何影响其临床病理表现尚不清楚。
这项回顾性单中心研究筛选了3398例肾移植活检样本,并将202例MVI≥2(班夫肾小球炎+肾小管周围毛细血管炎≥2)样本按中位发病时间9个月进行二分法比较。
移植肾中MVI≥2的患病率为12.4%,其功能衰竭比倾向匹配的正常对照组更频繁(n = 202;P < 0.001)。早期MVI≥2的流行病学危险因素包括移植肾功能延迟、既往AMR和循环供体特异性抗体(DSA+)。72.3%的患者既往有受者致敏情况。早期MVI≥2在65.3%的病例中被归类为AMR,在34.7%的病例中被归类为细胞性排斥反应,并且与正常对照肾相比,其功能恢复和移植物存活情况良好。晚期MVI≥2通过多变量流行病学模型预测与年轻(18 = 29岁)、女性受者、活体供肾、既往使用甲泼尼龙、环孢素(与他克莫司相比,水平<5 ng/mL)、未进行抗增殖治疗以及DSA+有关。不依从导致49.5%的病例,医源性因素导致47.5%的病例,通常是由于受者感染。晚期MVI≥2在93.1%的病例中是由AMR引起的,其特征是与早期MVI≥2或正常移植肾相比,间质纤维化、肾小管萎缩、肾小管周围毛细血管C4d染色阳性、肾小球毛细血管内皮C4d染色阳性、移植性肾小球病和血管病评分、DSA强度以及移植物衰竭更为严重。149例独特的MVI≥2肾的死亡校正移植物存活情况由不依从、血清肌酐、蛋白尿、DSA+、肾小管周围毛细血管班夫C4d染色阳性以及慢性间质纤维化评分独立决定。使用多变量Cox回归分析时,MVI评分和时间失去了显著性。
MVI≥2随时间变化的表达最好通过免疫抑制不足和AMR导致的微血管损伤差异来解释,这些差异影响了同种异体移植物的功能和存活。